Kraig Biocraft Laboratories (OTCQB: KBLB) has converted roughly half of its record 1.8 metric ton production of recombinant spider silk into usable fiber, a critical step that de-risks its manufacturing process and moves the biotech firm closer to commercial-scale inventory.
"Successfully converting that production into reeled silk is the next major step in transforming our spider silk technology into commercially available yarns and fabrics," Kim Thompson, Founder and CEO of Kraig Labs, said. "This is exactly the kind of operational execution we have been working toward."
The company confirmed that approximately 50% of the nearly 1.8 metric tons of cocoons from its latest production run are now reeled silk. Once completed, the full batch will represent the largest inventory of recombinant spider silk ever produced, intended to support product development and future commercial sales.
This achievement addresses two of the biggest challenges that have historically plagued the spider silk industry: scaling production to commercially relevant volumes and reliably converting that raw material into usable fiber. Success on both fronts positions Kraig Labs to potentially capture a share of a multi-billion-dollar market for advanced fibers sought by the defense, aerospace, and performance textile industries.
Kraig Labs' technology uses genetically engineered silkworms to produce fibers that incorporate spider silk proteins, aiming to replicate one of nature's strongest and most versatile materials. While the science has been proven for years, this milestone shifts the narrative from pure research to industrial-scale execution. The ability to build a substantial inventory is a prerequisite for securing large-scale commercial or military contracts.
The company's progress was recently featured on the cover of National Geographic's March 2026 issue, highlighting the firm's leading role in the effort to scale spider silk production.
For investors, the update reduces a key uncertainty: execution risk. By demonstrating it can not only produce in record-breaking quantities but also process that output efficiently, Kraig Labs appears to be lowering the barriers to revenue generation. The successful reeling operation provides tangible evidence of a functioning supply chain, a crucial element for a company transitioning from a development-stage biotech to an emerging materials supplier. The completion of the remaining 50% of the processing and any subsequent offtake agreements are the next key catalysts to watch.
This article is for informational purposes only and does not constitute investment advice.
